Events

Zimmer Biomet Ortho GmbH - Optipac Refobacin Plus Bone Cement III 의 리콜

New Zealand Medicines and Medical Devices Safety Authority에 따르면, 해당 리콜 는 New Zealand 에서 Biomet Orthopaedics Switzerland GmbH 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    20865
  • 사례 시작날짜
    2016-11-23
  • 사례 국가
    New Zealand
  • 사례 출처
    NZMMDSA
  • 사례 출처 URL
    https://medsafe.govt.nz/hot/Recalls/RecallSearch.asp
  • 비고 / 경고
    Data from New Zealand is current through July 2018. All of the data comes from the New Zealand Medicines and Medical Devices Safety Authority, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and New Zealand.
  • 데이터 추가 비고
    Recalling Organisation: Zimmer Biomet New Zealand Company, 210 Khyber Pass Road, Grafton, Auckland
  • 원인
    During internal investigation, it was identified that biomet orthopaedics cannot guarantee that the sterilization process for the optipac is fully compliant.
  • 조치
    Product to be returned to supplier

Device

Zimmer Biomet Ortho GmbH - Optipac Refobacin Plus Bone Cement III
  • 모델명 / 제조번호(시리얼번호)
    Model: , Affected: Optipac 40 Refobacin Plus Bone Cement, Optipac 60 Refobacin Plus Bone Cement, Optipac 80 Refobacin Plus Bone Cement, Optipac-S 40 Refobacin Plus Bone Cement, Optipac-S 60 Refobacin Plus Bone Cement, Optipac-S 80 Refobacin Plus Bone Cement
  • Manufacturer
    Biomet Orthopaedics Switzerland GmbH

Manufacturer

Biomet Orthopaedics Switzerland GmbH
  • 제조사 모회사 (2017)
    Zimmer Biomet Holdings
  • 제조사 의견
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    NZMMDSA